Vitamin C with steroids for gut graft-versus-host disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests whether adding vitamin C to standard steroid treatment helps control gut graft-versus-host disease (GVHD) after a stem cell transplant. It aims to reduce inflammation and improve symptoms with a treatment that is generally well-tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 5 years or older.
- You have gut GVHD that is moderate to severe, or mild gut GVHD with skin GVHD.
- You have not yet had strong immune-suppressing treatment for this GVHD, except for up to 3 days of steroids (with or without ruxolitinib).
- You are able to care for yourself (not bedridden).
- You do not have certain other medical conditions, like G6PD deficiency, sickle cell disease, or kidney stones.
- You agree to follow the study plan and come to the transplant center for visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether omega-3 fatty acids can help prevent acute graft-versus-host disease (aGVHD) in people receiving a stem cell transplant from a donor. Omega-3 may reduce inflammation and lower the chance of this serious complication.
This trial tests whether giving a fecal transplant (a procedure that transfers healthy bacteria from a donor's stool into your gut) can help children whose gut graft-versus-host disease (a common complication after a stem cell transplant) is not improving with standard steroid treatment.
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
This study tests a new cell therapy (CK0802) for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard steroid treatment. The treatment aims to control the immune response causing GVHD, potentially reducing symptoms and improving outcomes.
This study tests whether adding an investigational drug called Amimaitosai to standard steroids helps control gut symptoms caused by graft-versus-host disease after a stem cell transplant. It may offer a new option to reduce these symptoms and improve recovery.
Hear when a new Gastrointestinal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.